Charles River Laboratories International Inc (CRL)
Industry Diagnostics & Research
This stock can be held in an Investment Account
Sell
$81.00
Buy
$222.00
$1.13 (+0.83%)
Prices updated at 23 May 2025, 22:15 EDT
| Prices minimum 15 mins delay
Prices in USD
Charles River Laboratories International Inc is a pharmaceutical company providing drug discovery and development services. The company provides animal models for laboratory testing, and offers manufacturing testing services to various industries.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
---|---|
2024 | 32.88 |
2023 | 36.39 |
2022 | 36.79 |
2021 | 37.70 |
2020 | 36.72 |
2019 | 36.56 |
2018 | 37.07 |
2017 | 37.73 |
2016 | 38.30 |
Valuation data table
Year | Price / Sales |
---|---|
2025 | 1.75 |
2024 | 2.35 |
2023 | 2.89 |
2022 | 2.96 |
2021 | 5.65 |
2020 | 4.45 |
2019 | 2.98 |
2018 | 2.59 |
2017 | 2.87 |
2016 | 2.32 |
2015 | 2.86 |
Price/Forward earnings (YTD)
14.47
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
---|---|
2024 | 0.13 |
2023 | 6.01 |
2022 | 6.65 |
2021 | 6.25 |
2020 | 7.15 |
2019 | 5.90 |
2018 | 6.67 |
2017 | 4.37 |
2016 | 6.48 |
Debt profile data table
Year | Financial leverage |
---|---|
2024 | 2.17 |
2023 | 2.28 |
2022 | 2.55 |
2021 | 2.77 |
2020 | 2.60 |
2019 | 2.87 |
2018 | 2.93 |
2017 | 2.80 |
2016 | 3.24 |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.